n | mean | SD | p-value | |
---|---|---|---|---|
Acute GI 0 | 11 | 12.1 | 16.8 | 0.053 |
Acute GI I/II | 15 | 35.6 | 32.0 | |
Acute GI III/IV | 5 | 46.7 | 38.0 | |
Parametria ≤ 53 Gy expressed as equivalent dose in 2-Gy fractions (EQD2) with α/β = 10 | 19 | 14.0 | 23.1 | 0.057 |
Parametria > 53 Gy expressed as equivalent dose in 2-Gy fractions (EQD2) with α/β = 10 | 11 | 33.3 | 29.8 | |
Acute GI toxicity 0 | 11 | 9.4 | 8.6 | |
Acute GI toxicity I/II | 14 | 20.6 | 15.9 | |
Acute GI toxicity III/IV | 5 | 30.3 | 22.7 | |
Acute GU toxicity 0 | 5 | 14.3 | 12.9 | |
Acute GU toxicity I/II | 22 | 22.4 | 9.7 | |
Acute GU toxicity III/IV | 3 | 38.4 | 33.5 | |
≤ 49 years | 7 | 57.1 | 25.2 | |
50–59 years | 12 | 36.1 | 36.1 | |
60–69 years | 7 | 14.3 | 26.2 | |
≥ 70 years | 4 | 8.3 | 16.7 | |
T1/2 | 9 | 93.5 | 11.6 | |
T3/4 | 3 | 41.7 | 52.0 | |
Parametria ≤ 53 Gy expressed as equivalent dose in 2-Gy fractions (EQD2) with α/β = 10 | 8 | 96.9 | 6.2 | |
Parametria > 53 Gy expressed as equivalent dose in 2-Gy fractions (EQD2) with α/β = 10 | 4 | 47.9 | 44.2 | |
Parametria ≤ 53 Gy expressed as equivalent dose in 2-Gy fractions (EQD2) with α/β = 10 | 17 | 15.7 | 26.6 | |
Parametria > 53 Gy expressed as equivalent dose in 2-Gy fractions (EQD2) with α/β = 10 | 9 | 51.8 | 37.7 |
n | mean | SD | p-value | |
---|---|---|---|---|
Reference | 1309 | 74.5 | 15.5 | 0.001 |
Patients | 30 | 60.3 | 21.7 | |
Reference | 1309 | 91.5 | 15.5 | < 0.001 |
Patients | 30 | 73.6 | 19.6 | |
Reference | 1309 | 89.9 | 20.6 | < 0.001 |
Patients | 31 | 58.1 | 33.0 | |
Reference | 1309 | 83.2 | 19.3 | 0.001 |
Patients | 31 | 65.1 | 26.7 | |
Reference | 1309 | 93.4 | 14.6 | < 0.001 |
Patients | 31 | 73.2 | 28.4 | |
Reference | 1309 | 93.3 | 17.1 | < 0.001 |
Patients | 31 | 69.9 | 29.0 | |
Reference | 1309 | 16.4 | 21.4 | < 0.001 |
Patients | 31 | 51.6 | 28.0 | |
Reference | 1309 | 2.4 | 9.6 | 0.030 |
Patients | 31 | 11.3 | 21.7 | |
Reference | 1309 | 17.0 | 24.2 | 0.025 |
Patients | 31 | 26.9 | 24.2 | |
Reference | 1309 | 7.2 | 18.7 | 0.020 |
Patients | 30 | 18.9 | 25.8 | |
Reference | 1309 | 13.0 | 23.6 | < 0.001 |
Patients | 31 | 40.9 | 36.2 | |
Reference | 1309 | 4.2 | 13.9 | 0.002 |
Patients | 31 | 21.5 | 27.7 | |
Reference | 1309 | 3.1 | 12.1 | < 0.001 |
Patients | 31 | 22.6 | 27.7 | |
Reference | 1309 | 2.9 | 12.7 | < 0.001 |
Patients | 31 | 29.0 | 30.7 | |
Reference | 1309 | 4.8 | 16.3 | < 0.001 |
Patients | 31 | 29.0 | 29.5 |
Radiotherapy dose in EQD2 (α/β = 10) | ||||
---|---|---|---|---|
Median EBRT | 44 Gy | |||
Range EBRT | 35–51 Gy | |||
Median parametria | 53 Gy | |||
Range parametria | 38–67 Gy | |||
Median HDR-BT | 40 Gy | |||
Range HDR-BT | 10–50 Gy | |||
IMRT | 58 | 69.9% | ||
3D-conformal | 25 | 30.1% | ||
No boost | 36 | 43.4% | ||
Sequential | 31 | 37.3% | ||
SIB | 16 | 19.3% | ||
≤ 53 Gy | 56 | 67.5% | ||
> 53 Gy | 27 | 32.5% | ||
Cisplatin 40 mg/m2 | 71 | 85.5% | ||
None | 12 | 14.5% | ||
< 6 weeks | 9 | 10.8% | ||
6-8 weeks | 52 | 62.7% | ||
≥ 9 weeks | 22 | 26.5% | ||
min. Hb < 10 g/dl | 38 | 45.8% | ||
min. Hb ≥ 10 g/dl | 45 | 54.2% | ||
≤ 2 ECs | 69 | 83.1% | ||
> 2 ECs | 14 | 16.9% | ||
Grade 0 | 33 | 39.8% | ||
Grade I | 15 | 18.1% | ||
Grade II | 20 | 24.1% | ||
Grade III | 12 | 14.5% | ||
Grade IV | 3 | 3.6% | ||
Grade 0 | 15 | 18.1% | ||
Grade I | 34 | 41.0% | ||
Grade II | 28 | 33.7% | ||
Grade III | 6 | 7.2% |
Age | ||
---|---|---|
Median | 57 years | |
Range | 32–90 years | |
Squamous cell carcinoma | 67 | 80.7% |
Adenocarcinoma | 14 | 16.9% |
Adenosquamous carcinoma | 2 | 2.4% |
G1 | 8 | 9.6% |
G2 | 24 | 28.9% |
G3 | 35 | 42.2% |
GX | 16 | 19.3% |
I | 2 | 2.4% |
II | 4O | 48.2% |
III | 15 | 18.1% |
IV | 26 | 31.3% |
T1 | 3 | 3.6% |
T2 | 46 | 55.4% |
T3 | 25 | 30.1% |
T4 | 9 | 10.8% |
N0 | 28 | 33.7% |
N1 | 55 | 66.3% |
M0 | 64 | 77.1% |
M1a | 12 | 14.5% |
M1c | 7 | 8.4% |
OS | Univariate analysis (log-rank test) | ||
---|---|---|---|
Mean (months) | p-value | ||
FIGO I/II | 72.6 | ||
FIGO III/IV | 50.8 | ||
T1/2 | 69.2 | ||
T3/4 | 50.4 | ||
G1/2 | 72.4 | 0.053 | |
G3 | 50.5 | ||
yes | 69.9 | ||
no | 51.2 | ||
≤ 50 Gy | 50.7 | ||
> 50 Gy | 71.5 | ||
≤ 53 Gy | 59.5 | 0.194 | |
> 53 Gy | 64.1 | ||
yes | 67.4 | ||
no | 32.1 | ||
6–8 weeks | 71.6 | ||
≥ 9 weeks | 44.7 | ||
min. Hb < 10 g/dl | 52.1 | ||
min. Hb ≥ 10 g/dl | 70.3 | ||
≤ 2 ECs | 67.6 | ||
> 2 ECs | 41.6 | ||
FIGO I/II | 85.9 | 0.072 | |
FIGO III/IV | 66.7 | ||
T1/2 | 85.7 | ||
T3/4 | 64.1 | ||
yes | 84.1 | 0.095 | |
no | 56.1 | ||
N0 | 85.6 | ||
N1 | 61.0 | ||
M0/M1a | 75.2 | ||
M1c | 37.1 | ||
G1/2 | 84.6 | ||
G3 | 59.8 | ||
yes | 0.417 | 0.192-0.900 | |
no | Reference | ||
yes | 0.382 | 0.152-0.961 | |
no | Reference | ||
T1/2 | Reference | ||
T3/4 | 2.668 | 1.032-6.896 | 0.043 |
N0 | Reference | ||
N1 | 4.383 | 1.003-19.154 | |
M0/M1a | Reference | ||
M1c | 4.646 | 1.466-14.719 |